Freelance Pharmaceutical And Biotech Writer
Nick Paul Taylor is a Freelance Pharmaceutical and Biotech Writer. He specializes in medicine and healthcare, focusing on pharmaceutical manufacturing, regulation, and the intersection of health technology and business. His work has been featured in prominent publications such as Healthcare Dive, BioPharma Dive, and Yahoo Finance.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Nick Paul Taylor's articles are focused on the healthcare and pharmaceutical industry, particularly highlighting data-driven content. His coverage centers around medical technology, pharmaceutical companies, clinical trials, drug development, and biotechnology.
Given his focus on citing data and press releases, Nick is likely to be interested in pitches that provide newsworthy statistics or insights from credible sources within the healthcare and pharmaceutical sectors. He may also respond well to pitches related to government announcements impacting these industries.
As he does not have a specific geographic focus mentioned but covers global pharmaceutical news extensively, consider providing international perspectives or insights when reaching out for potential collaboration.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The acquisition is the latest in a series of agreements between DePuy Synthes and organizations associated with entrepreneur Stéphane Lavallée.
Eli Lilly has successfully challenged Noom's “A Smaller Dose. A Smarter Start” claim, leading the National Advertising Division (NAD) to recommend the digital health company change or drop the statement.
Kaléo has launched the “AUVI-Q Speaks Up” campaign to share patients', caregivers' and healthcare providers' stories about life with severe allergies.
By: Nick Paul Taylor
The FDA has
By: Nick, Paul Taylor
Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by striking a broad pact that positions Pfizer to leverage China's fast early development system.
By: Nick, Paul Taylor
Philips has integrated animated Disney characters and stories into MRI machines to make imaging scans more comforting and engaging for children.
By: Nick Paul Taylor
Pharma companies need to strengthen and modernize patient support programs to reflect rising rates of cancer in adults aged 18 to 49 years, an Omnicom Health report found.
By: Nick, Paul Taylor
AstraZeneca has shared data it believes can rescue anselamimab from a phase 3 failure, linking the drug candidate to a 62% improvement in survival among a prespecified subgroup of patients with light chain (AL) amyloidosis.
By: Nick, Paul Taylor
FDA inspectors found Alchymars failed to adequately maintain equipment used to make active pharmaceutical ingredients for the U.S. market. Over-the-counter drugmakers GC America and Sato Pharmaceutical also received warning letters.
Johnson & Johnson asked customers to quarantine and return affected products. A spokesperson said J&J conducted quality system audits as part of its integration of Abiomed that resulted in some field actions.
